Zevra Therapeutics, Inc.

Good afternoon and thank you for joining Zavra's second quarter 2026 financial results and corporate update conference call. Today's call is being recorded and will be available via the investor relations section of the company's website later today.

The host for today's call is Nichol Ochsner, Zavra's Vice President of Investor Relations and Corporate Communications.

Thank you, and welcome to those who are joining us. Today, we will provide an overview of our recent accomplishments, followed by a review of our second quarter 2026 financial results. I encourage you to read our financial results news release, which was distributed this afternoon and is available in the investor section of our website. Before we begin the call, please note that certain information shared today will include forward-looking statements. Actual results may differ materially from those stated or implied by any forward-looking statements due to risks and uncertainties associated with Debra's business. Follow-looking statements are not promises or guarantees and are inherently subject to risks, uncertainties, and other important factors that may lead to actual results differing materially from the projections made and should be evaluated together with the risk factor section in our most recent quarterly report on Form 10-Q, our annual report on Form 10-K, and our other filings with the SEC. This call will also reference Thank you for joining us. I am pleased to welcome Zebra's management team members participating in today's call. Neil McFarlane, Zebra's President and Chief Executive Officer, Josh Schafer, our Chief Commercial Officer, and Justin Renz, our Chief Financial Officer. Now, it's my pleasure to hand the call over to Neil.